Skip to main content

Vycor Medical, Inc.

corporate_fare Company Profile

Vycor Medical, Inc.

VYCO·OTC·Industrial Applications And Services·CIK 0001424768

Vycor Medical, Inc. provides innovative surgical and therapeutic solutions within the medical device industry, operating two distinct business units. Vycor Medical designs, develops, and markets medical devices for neurosurgery. Its key product, the ViewSite Brain Access System ("VBAS"), is a next-generation retraction and access system. Vycor Medical holds ISO 13485:2016 and MDSAP certifications, and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (MDD Class III) for brain and spine surgeries, along with regulatory approvals in other international markets. The second business unit, NovaVision, offers non-invasive, computer-based rehabilitation therapies for individuals with vision disorders caused by neurological brain damage, such as from a stroke. Both businesses utilize minimally or non-invasive approaches. The company was formed on June 17, 2005, as Vycor Medical LLC, converted to a Delaware corporation on August 14, 2007, and changed its name to Vycor Medical, Inc. Its listing became effective in February 2009. On November 29, 2010, Vycor acquired substantially all assets of NovaVision, Inc., and on January 4, 2012, through its NovaVision subsidiary, acquired all shares of Sight Science Limited.

Vycor Medical, Inc. (OTC:VYCO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 6 items for VYCO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 6 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for VYCO spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Vycor Q3 2026: Revenue Down 19%, Going Concern Doubt Reaffirmed
  • Vycor Medical Q2 Revenue Falls 16% as Going Concern Warning Looms
  • Vycor Medical Q2 2026: Going Concern Warning, Material Weakness, Revenue Down 16%
  • Vycor Medical Reports Q1 Profitability & Positive Cash Flow Amidst Going Concern Doubt
  • Vycor Medical Reports 17% Revenue Growth, Achieves Operating Profit in 2025

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.86M
Net Income
-$72.43K
Diluted EPS
-$0.01
Op. Cash Flow
-$13.47K
Free Cash Flow
-$18.7K
Gross Profit
$1.56M
Operating Income
$33.9K
Cash & Equivalents
$86.98K
Total Debt
$135.83K
Debt / Equity
-0.03×
Net Margin
-3.9%
Shares Outstanding
33.37M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014036
Browse all tickers starting with V →
$0.044
52-week range · as of 2026-11-13 $0.017 – $0.50
Market cap
$1.47M
Volume
3.3K (0.1× avg)
3-mo avg 38K
Live data · 2026-11-22 07:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VYCO - Latest Insights

VYCO
Nov 13, 2026, 12:43 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.044
Real-time Price: $0.044 info
Change: $0 (0%) info
Market Cap: $1.468M info
VYCO
Aug 14, 2026, 4:20 PM EDT
Source: EQS
Importance Score:
7
Price at Filing: $0.069
Real-time Price: $0.044 info
Change: -$0.025 (-36%) info
Market Cap: $1.468M info
VYCO
Aug 14, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.069
Real-time Price: $0.044 info
Change: -$0.025 (-36%) info
Market Cap: $1.468M info
VYCO
May 15, 2026, 2:53 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0699
Real-time Price: $0.044 info
Change: -$0.0259 (-37%) info
Market Cap: $1.468M info
VYCO
Mar 31, 2026, 3:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.090
Real-time Price: $0.044 info
Change: -$0.046 (-51%) info
Market Cap: $1.468M info
VYCO
Mar 31, 2026, 2:35 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.090
Real-time Price: $0.044 info
Change: -$0.046 (-51%) info
Market Cap: $1.468M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets